Conditions: Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified; Refractory Nodal Marginal Zone Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation; Drug: Carboplatin; Drug: Cytarabine; Drug: Dexamethasone; Biological: Epcoritamab; Drug: Etoposide Phosphate; Drug: Gemcitabine; Drug: Ifosfamide; Procedure: Multigated Acquisition Scan; Drug: Oxaliplatin; Biological: Rituximab
Sponsors: University of California, Davis; National Cancer Institute (NCI)
Not yet recruiting Conditions: Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified; Refractory Nodal Marginal Zone Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation; Drug: Carboplatin; Drug: Cytarabine; Drug: Dexamethasone; Biological: Epcoritamab; Drug: Etoposide Phosphate; Drug: Gemcitabine; Drug: Ifosfamide; Procedure: Multigated Acquisition Scan; Drug: Oxaliplatin; Biological: Rituximab
Sponsors: University of California, Davis; National Cancer Institute (NCI)
Not yet recruiting
